Endocrinology & Metabolism Clinical Trials

Statistical methods in endocrinology & metabolism trials

The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.

All endocrinology & metabolism trials

1,009 results

• Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients: Complete Statistical AnalysisIndependent statistical analysis of Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 36NCT00871845
• Incretins in Impaired Fasting Glucose: Complete Statistical AnalysisIndependent statistical analysis of Incretins in Impaired Fasting Glucose: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00364377).Phase 4Results postedn = 22NCT00364377
• Influence of a Monopoly Game on Subtle Behaviors: Complete Statistical AnalysisIndependent statistical analysis of Influence of a Monopoly Game on Subtle Behaviors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02470949).Phase NAResults postedn = 9NCT02470949
• Influenza Vaccination Digital Interventions for People Living With Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Influenza Vaccination Digital Interventions for People Living With Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03870997).Phase NAResults postedn = 94,321NCT03870997
• INSIGHTIndependent statistical analysis of Extension Study to Study PQ-110-001 (NCT03140969): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03913130).Phase 1/2Results postedn = 9NCT03913130
• inTandem3Complete statistical analysis of the phase 3 inTandem3 trial of sotagliflozin in patients with type 1 diabetes and inadequate glycemic control with insulin therapy alone, including trial design, endpoints, statistical methodology, results,…Phase 3Results postedn = 1,405NCT02531035
• Investigation of a New Diet for the Treatment of Obesity in the NHS: Complete Statistical AnalysisIndependent statistical analysis of Investigation of a New Diet for the Treatment of Obesity in the NHS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase NAResults postedn = 21NCT05249439
• Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.: Complete Statistical AnalysisIndependent statistical analysis of Investigations of the Optimum Serum Bicarbonate Level in Renal Disease.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01574157).Phase NAResults postedn = 74NCT01574157
• IONMIndependent statistical analysis of Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00191282).Phase 4Results postedn = 1,116NCT00191282
• IOPAIndependent statistical analysis of A Study for Patients With Diabetes Mellitus (IOPA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00420095).Phase 4Results postedn = 117NCT00420095
• iPOP-UPIndependent statistical analysis of Dissemination and Implementation of Improving Pediatric Obesity Practice Using Prompts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05627011).Phase NAResults postedn = 58,364NCT05627011
• IRISComplete statistical analysis of the IRIS trial of pioglitazone versus placebo after stroke or myocardial infarction, including trial design, time-to-event endpoints, Cox modeling, mixed-effects analysis, multiplicity, interim analysis, results, and statistical interpretation.Phase 3Results postedn = 3,876NCT00091949
• IRMAIndependent statistical analysis of Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 4Results postedn = 33NCT02252406
• Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 2Results postedn = 61NCT00053365
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA): Complete Statistical AnalysisIndependent statistical analysis of Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…Phase 3Results postedn = 1,512NCT02940886
• Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease: Complete Statistical AnalysisIndependent statistical analysis of Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 1,538NCT02940860
• IRONMANAn independent statistical analysis of IRONMAN (NCT02642562), a randomized phase 4 trial of intravenous ferric derisomaltose in patients with chronic heart failure and iron deficiency.Phase 4n = 1,160NCT02642562
• Islet Transplantation for Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Islet Transplantation for Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00014911).Phase 2Results postedn = 36NCT00014911
• ISS-DMIIIndependent statistical analysis of Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 4Results postedn = 4NCT03258281
• J-DOIT3An independent statistical analysis of J-DOIT3 (NCT00300976), a randomized parallel-group study of integrated lifestyle treatment for major cardiovascular risk factors in people with type 2 diabetes.Phase NAn = 2,542NCT00300976
• Jump StartIndependent statistical analysis of Jump Start Shared Medical Appointments for Diabetes With Weight Management: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01973972).Phase NAResults postedn = 263NCT01973972
• Juno Perth Clinical Trial: Complete Statistical AnalysisIndependent statistical analysis of Juno Perth Clinical Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02317042).Phase NAResults postedn = 25NCT02317042
• KAMELEONIndependent statistical analysis of A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors: primary endpoint results, effect estimate with confidence…Phase 2Results postedn = 20NCT02999672
• Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study: Complete Statistical AnalysisIndependent statistical analysis of Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 4Results postedn = 80NCT01997515
• ktpumpIndependent statistical analysis of Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00574405).Phase NAResults postedn = 24NCT00574405
• La ComunidadIndependent statistical analysis of Latinos Combating Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01831921).Phase NAResults postedn = 225NCT01831921
• Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients: Complete Statistical AnalysisIndependent statistical analysis of Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00383708).Phase 3Results postedn = 125NCT00383708
• LANTERNIndependent statistical analysis of Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly: primary endpoint results, effect estimate with confidence interval,…Phase 3Results postedn = 128NCT02493517
• Late-Onset Treatment Study Extension Protocol: Complete Statistical AnalysisIndependent statistical analysis of Late-Onset Treatment Study Extension Protocol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00455195).Phase 4Results postedn = 81NCT00455195
• LBLIndependent statistical analysis of Harmonic Versus Electro Surgery in Lower Body Lift Procedures: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00522171).Phase NAResults postedn = 30NCT00522171
• LCIOADMT2Independent statistical analysis of Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…Phase 3Results postedn = 256NCT02371759
• LENSIndependent statistical analysis of Lowering Events in Non-proliferative Retinopathy in Scotland: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03439345).Phase 4Results postedn = 1,151NCT03439345
• Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency: Complete Statistical AnalysisIndependent statistical analysis of Lentiviral (LV) Gene Therapy for Adenosine Deaminase (ADA) Deficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380990).Phase 1/2Results postedn = 36NCT01380990
• Less Infections for the Diabetic Foot: Complete Statistical AnalysisIndependent statistical analysis of Less Infections for the Diabetic Foot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03615807).Phase NAResults postedn = 182NCT03615807
• LIDSIndependent statistical analysis of A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 2/3Results postedn = 90NCT05276063
• LifeFlow Fluid Study- Non- Critical Pediatric Patients Having a Trans Abdominal Ultrasound: Complete Statistical AnalysisIndependent statistical analysis of LifeFlow Fluid Study- Non- Critical Pediatric Patients Having a Trans Abdominal Ultrasound: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase NAResults postedn = 30NCT03712189
• Lifestyle Intervention in Preparation for Pregnancy (LIPP): Complete Statistical AnalysisIndependent statistical analysis of Lifestyle Intervention in Preparation for Pregnancy (LIPP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03146156).Phase NAResults postedn = 143NCT03146156
• Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone: Complete Statistical AnalysisIndependent statistical analysis of Linagliptin Versus Placebo in Type 2 Diabetic Patients With Inadequate Glycaemic Control on Metformin in Combination With Pioglitazone: primary endpoint results, effect estimate with confidence interval, sample-size planning…Phase 3Results postedn = 278NCT00996658
• Lipid Metabolism in Gestational Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Lipid Metabolism in Gestational Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00534105).Phase NAResults postedn = 106NCT00534105
• Liraglutide in Adolescents With Type 1 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Liraglutide in Adolescents With Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02516657).Phase 3Results postedn = 5NCT02516657
• Litramine in Weight Maintenance: Complete Statistical AnalysisIndependent statistical analysis of Litramine in Weight Maintenance: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01505387).Phase 4Results postedn = 50NCT01505387
• LixiBITIndependent statistical analysis of Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 3Results postedn = 10NCT02168491
• LoGoIndependent statistical analysis of Low-dose Gonal-f® in Ovulation Induction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01871532).Phase 4Results postedn = 24NCT01871532
• LOGRIBMETIndependent statistical analysis of Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase NAResults postedn = 115NCT01896050
• Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes – a Randomized Pragmatic Trial: Complete Statistical AnalysisIndependent statistical analysis of Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial:…Phase 4Results postedn = 1,278NCT03596450
• Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study: Complete Statistical AnalysisIndependent statistical analysis of Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…Phase 1/2Results postedn = 187NCT03733249
• Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome): Complete Statistical AnalysisIndependent statistical analysis of Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…Phase 3Results postedn = 173NCT01415427
• Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD): Complete Statistical AnalysisIndependent statistical analysis of Long-term Metazym Treatment of Patients With Late Infantile Metachromatic Leukodystrophy (MLD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 1/2Results postedn = 13NCT00633139
• Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia: Complete Statistical AnalysisIndependent statistical analysis of Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…Phase 2Results postedn = 1NCT01597440
• Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Long-Term Safety Study Of Inhaled Insulin (CP-464,005, Inhaler) In Japanese Patients With Type1 or Type2 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…Phase 3Results postedn = 24NCT00527397

← All therapeutic areas